Glenmark Pharmaceuticals . Sees -3.31% Decline in Stock Price, Remains Strong Player in Industry
On October 29, 2024, Glenmark Pharmaceuticals ., a largecap pharmaceutical company, saw a -3.31% decline in its stock price, earning a 'Hold' rating from MarketsMojo. The stock's performance was -2.2% lower than the sector average, but its moving averages show a positive trend. Despite recent decline, Glenmark remains a strong player in the industry.
Glenmark Pharmaceuticals ., a largecap pharmaceutical company, saw a decline of -3.31% in its stock price on October 29, 2024. This underperformance was reflected in the stock's 'Hold' rating given by MarketsMOJO.
The stock's performance today was -2.2% lower than the sector average. It touched an intraday low of Rs 1663.2, a decrease of -3.3%. However, the stock's moving averages show a positive trend, with it being higher than the 100 day and 200 day moving averages.
In comparison to the overall market performance, Glenmark Pharmaceuticals . saw a decline of -3.78% while the Sensex only saw a decrease of -0.46%. Over the past month, the stock's performance was -1.91% compared to the Sensex's -6.94%.
Despite the recent decline in stock price, Glenmark Pharmaceuticals . remains a strong player in the pharmaceutical industry. With its largecap size, the company has a solid foundation and is well-positioned for future growth. Investors should continue to monitor the stock's performance and make informed decisions based on their own research and analysis.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Momentum
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Activity
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Momentum
Most Read
